Mwandishi:
Mhariri:
ULY CLINIC
Dkt. Benjamin L, MD
16 Juni 2021 19:37:31
Omeprazole na ujauzito
Omeprazole ni dawa kundi la PPI inayofanya kazi ya kuzuia tezi za parieto kuzalisha tindikali tumboni. Dawa hii hutumika katika matibabu ya vidonda vya tumbo, kucheua tindikali, kuungua umio kwa tindikali na magonjwa mengine yatokanayo na uzalishaji mkubwa wa tindikali tumboni kama sindromu ya Zollinger-Ellison.
Taarifa za tafiti zimeonyesha kuwa dawa za PPI zina hatari kidogo kwenye ujauzito, licha ya kuwa na taarifa chache za uzoefu wa matumizi yake kwa binadamu wajawazito. Kuna tafiti iliyoonyesha mahusiano ya aleji na pumu kwa watoto waliozaliwa na mama aliyetumia dawa hii, hata hivyo inahitaji tafiti nyingi zaidi kufanyika ili kuhakiki mada hayo. Madhaifu ya kiuumbaji kama madhaifu ya moyo yameonekana kuhusiana na matumizi ya dawa jamii ya PPI lakini hakuna ushahidi kuwa dawa hizi ni kisababishi cha moja kwa moja na tafiti zaidi zinahitajika kufanyika.
Endapo dawa hii itatumika kwa bahati mbaya au kwa makusudi kwenye kipindi cha kwanza cha ujauzito, hatari kwa kijusi tumboni inachukuliwa kuwa ndogo, hata hivyo watoto wanaozaliwa wanatakiwa kufuatiliwa kwa muda mrefu kuona nini kitatokea kwao.
Uzito wa dawa hii ni mdogo sana hivyo dawa ina uwezo wa kupita na kuingia kwenye maziwa ya mama na kumpata mtoto anayenyonya. Kuna taarifa ya tafiti moja kuhusu matumizi ya dawa hii kwa mama anayenyonyesha na imeonyesha mtoto alikuwa anaendelea vema hadi kwenye umri wa mwaka mmoja.
Licha ya kutokuwepo taarifa nyingi zinazoelezea matumizi kwa mama anayenyonyesha, dawa hii ni vema ikaepukwa kwa mama anayenyonyesha kwa jinsi inavyowezekana kutokana na tafiti za wanyama kuonyesha kuwa ina hatari ya kusababisha saratani na kuzuia uzalishaji wa tindikali kwa kiasi kikubwa.
Ushauri dhidi ya matumizi kwa mama mjamzito
Taarifa za binadamu zinaonyesha hatari kidogo ya madhara kwa kijusi-kichanga
Taarifa za binadamu zinaonyesha hatari kidogo ya madhara kwa kijusi-kichanga ina maana gani?
Kuna taarifa chache za uzoefu wa matumizi kwa binadamu kutoka kwenye dawa hii au dawa zilizo kundi moja au zinazofanana namna zinavyofanya kazi yake. Ikijumuisha ujauzito miezi mitatu ya kwanza, inaonyesha kuwa, dawa hii haiwakilishi kuwa na hatari yenye mashiko ya kuwa sumu kwa kichanga tumboni kuweza kusababisha madhaifu ya uumbaji, ukuaji, viungo vya mwili, ufanyaji kazi wa viungo, tabia au kusababisha kifo endapo itatumika muda wowote ule kwenye ujauzito. Taarifa chache za uzoefu wa matumizi kwa binadamu zinafanya taarifa za uzazi wa wanyama kutokuwa na mashiko.
Ushauri wa matumizi kwa mama anayenyonyesha
Hakuna (chache) taarifa za binadamu- Inauwezekano mkubwa kuwa sumu
Hakuna (chache) taarifa za binadamu- Inauwezekano mkubwa kuwa sumu ina maana gani?
Hakuna taarifa za uzoefu kuhusu matumizi ya dawa hii kwa mama anayenyonyesha au kuna taarifa chache. Sifa za ufanyaji kazi wa dawa zinaonyesha kuwa dawa hii inaweza kuwa sumu kwa kichanga anayenyonya. Dawa hii isitumike kwa mama anayenyonyesha.
ONYO: Usitumie dawa yoyote bila ushauri wa daktari. Dawa zinaweza kuleta madhara mwilini na pia matumizi ya baadhi ya dawa pasipo ushauri na vipimo husababisha vimelea kuwa sugu dhidi ya dawa hiyo.
ULY clinic inakushauri kuwasiliana na daktari wako unapotaka kuchukua maamuzi yoyote yanayohusu afya yako.
Wasiliana na daktari/Mfamasia wa ULY clinic kwa ushauri na Tiba au kuandikiwa dawa kwa kupiga simu au Kubonyeza Pata tiba chini ya tovuti hii.
Imeboreshwa,
22 Aprili 2022 15:43:39
Rejea za mada hii;
1. Ching MS, Morgan DJ, Mihaly GW, Hardy KF, Smallwood RA. Placental transfer of omeprazole in maternal and fetal sheep. Dev Pharmacol Ther 1986;9:323–31.
2. Moore J, Flynn RJ, Sampaio M, Wilson CM, Gillon KRW. Effect of single-dose omeprazole on intragastric acidity and volume during obstetric anaesthesia. Anaesthesia 1989;44:559–62.
3. Tsirigotis M, Yazdani N, Craft I. Potential effects of omeprazole in pregnancy. Hum Reprod 1995;10:2177–8.
4. Harper MA, McVeigh JE, Thompson W, Ardill JES, Buchanan KD. Successful pregnancy in association with Zollinger-Ellison syndrome. Am J Obstet Gynecol 1995;173:863–4.
5. Kallen B. Delivery outcome after the use of acid-suppressing drugs in early pregnancy with special reference to omeprazole. Br J Obstet Gynaecol 1998;105:877–81.
6. Kallen BAJ. Use of omeprazole during pregnancy—no hazard demonstrated in 955 infants exposed during pregnancy. Eur J Obstet Gynecol Reprod Biol 2001;98:63–8.
7. Lalkin A, Loebstein R, Addis A, Ramezani-Namin F, Mastroiacovo P, Mazzone T, Vial T, Bonati M, Koren G. The safety of omeprazole during pregnancy: a multicenter prospective controlled study. Am J Obstet Gynecol 1998;179:727–30.
8. Wilton LV, Pearce GL, Martin RM, Mackay FJ, Mann RD. The outcomes of pregnancy in women exposed to newly marketed drugs in general practice in England. Br J Obstet Gynaecol 1998;105:882– 9.
9. Brunner G, Meyer H, Athmann C. Omeprazole for peptic ulcer disease in pregnancy. Digestion 1998;59:651–4.
10. Nielsen GL, Sorensen HT, Thulstrup AM, Tage-Jensen U, Olesen C, Ekbom A. The safety of proton pump inhibitors in pregnancy. Aliment Pharmacol Ther 1999;13:1085–9.
11. Ruigomez A, Rodriguez LAG, Cattaruzzi C, Troncon MG, Agostinis L, Wallander MA, Johansson S. Use of cimetidine, omeprazole, and ranitidine in pregnant women and pregnancy outcomes. Am J Epidemiol 1999;150:476–81.
12. Marshall JK, Thomson ABR, Armstrong D. Omeprazole for refractory gastroesophageal reflux disease during pregnancy and lactation. Can J Gastroenterol 1998;12:225–7.
13. Nikfar S, Abdollahi M, Moretti ME, Magee LA, Koren G. Use of proton pump inhibitors during pregnancy and rates of major malformations: a meta-analysis. Dig Dis Sci 2002;47:1526–9.
14. Diav-Citrin O, Arnon J, Shechtman S, Schaefer C, Van Tonningen MR, Clementi M, De Santis M, Robert-Gnansia E, Valti E, Malm H, Ornoy A. The safety of proton pump inhibitors in pregnancy: a multicentre prospective controlled trial. Aliment Pharmacol Ther 2005;21:269–75.
15. Dehlink E, Yen E, Leichtner AM, Hait EJ, Fiebiger E. First evidence of a possible association between gastric acid suppression during pregnancy and childhood asthma: a population-based register study. Clin Exp Allergy 2009;39:246–53.
16. Yau G, Kan AF, Gin T, Oh TE. A comparison of omeprazole and ranitidine for prophylaxis against aspiration pneumonitis in emergency caesarean section. Anaesthesia 1992;47:101–4.
17. Orr DA, Bill KM, Gillon KRW, Wilson CM, Fogarty DJ, Moore J. Effects of omeprazole, with and without metoclopramide, in elective obstetric anaesthesia. Anaesthesia 1993;48:114–9.
18. Rocke DA, Rout CC, Gouws E. Intravenous administration of the proton pump inhibitor omeprazole reduces the risk of acid aspiration at emergency cesarean section. Anesth Analg 1994;78:1093–8.
19. Gin T. Intravenous omeprazole before emergency cesarean section. Anesth Analg 1995;80:848.
20. Rocke DA, Rout CC. Intravenous omeprazole before emergency cesarean section. Anesth Analg 1995;80:848–9.
21. Stuart JC, Kan AF, Rowbottom SJ, Gin T. Acid aspiration prophylaxis for emergency caesarean section. Anaesthesia 1996;51:415–21.
22. Gill SK, O’Brien L, Einarson TR, Koren G. The safety of proton pump inhibitors (PPIs) in pregnancy: a meta-analysis. Am J Gastroenterol 2009;104:1541–5.
23. Pasternak B, Hviid A. Use of proton-pump inhibitors in early pregnancy and the risk of birth defects. N Engl J Med 2010;363:2114–23.
24. Mitchell AA. Proton-pump inhibitors and birth defects—some reassurance, but more needed. N Engl J Med 2010;363:2161–3.
25. Anderka M, Mitchell AA, Louik C, Werler MM, Hernandez-Diaz S, Rasmussen SA, and the National Birth Defects Prevention Study. Medications used to treat nausea and vomiting of pregnancy and the risk of selected birth defects. Birth Defects Res A Clin Mol Teratol 2012;94:22–30.
26. Erichsen R, Mikkelsen E, Pedersen L, Sorensen HT. Maternal use of proton pump inhibitors during early pregnancy and the prevalence of hypospadias in male offspring. Am J Ther 2012 (Feb 3). [Epub ahead of print].
27. Matok I, Levy A, Wiznitzer A, Uziel E, Koren G, Gorodischer R. The safety of fetal exposure to protonpump inhibitors during pregnancy. Dig Dis Sci 2012;57:699–705.
28. Broussard CN, Richter JE. Treating gastro-oesophageal reflux disease during pregnancy and lactation. What are the safest therapy options? Drug Saf 1998;19:325–37.
29. Katz PO, Castell DO. Gastroesophageal reflux disease during pregnancy. Gastroenterol Clin N Am 1998;27:153–67.
30. Ramakrishnan A, Katz PO. Pharmacologic management of gastroesophageal reflux disease. Curr Treat Options Gastroenterol 2002;5:301–10.
31. Richter JE. Gastroesophageal reflux disease during pregnancy. Gastroenterol Clin N Am 2003;32:235– 61.
32. Richter JE. Review article: the management of heartburn in pregnancy. Aliment Pharmacol Ther 2005;22:749–57.